ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
SAFE-IOERT prospective study: clinical outcomes of exclusive intraoperative radiotherapy in early breast cancer according to molecular subtype and tumor-infiltrating lymphocytes.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PURPOSE AND
objectivesIntraoperative electron radiotherapy (IOERT) can be applied during breast conserving surgery to treat invasive breast cancer. Tumor-infiltrating lymphocytes (TILs) are fundamental elements of the specific immunological response against tumor cells and have prognostic importance in many types of cancer. The aim of the study was to analyze the local recurrence rate, adverse effects, surrogate molecular subtype, and stromal percentage of TILs in patients with breast cancer treated with exclusive IOERT. MATERIALS AND
methodsEighty-one patients with early-stage breast carcinoma were included in a prospective study and were treated performing a conservative surgery, followed by IOERT with a dose of 20 Gy as accelerated partial breast irradiation (APBI). TILs were evaluated in hematoxylin-eosin sections of surgical specimens before IOERT.
resultsThe median follow-up of the patients was 58 months (range 15-128). Fifty-eight patients (71.6%) were classified as Luminal A-like, 21 patients (25.9%) Luminal B-like and 2 patients (2.5%) were classified as HER2 positive-like. The local recurrence rate was 2.5%. Two patients presented ipsilateral local recurrence, and one patient presented distant recurrence. Eight patients (9.9%) suffered chronic toxicity with grade 1 localized fibrosis, fat necrosis, and pain. Eighty-one percent of stromal TILs were low and 14.9% were intermediate. In 3 patients (4.1%) the stromal percentage of TILs could not be assessed.
conclusionsIn this prospective cohort of carefully selected patients with early breast cancer, exclusive IOERT delivered as accelerated partial breast irradiation achieved favourable local control with minimal chronic toxicity. Predominantly low stromal TIL levels in luminal-like tumours may be associated with recurrence risk. Larger prospective studies are needed for validation.
Indexed as
Identifiers
42258139What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.